- Bacterial pneumonia
:"See
pneumonia for a general overview of pneumonia and its other causes."-), "Klebsiella pneumoniae " (ICD10|J|15|0|j|10), "Escherichia coli " (ICD10|J|15|5|j|10), "Pseudomonas aeruginosa" (ICD10|J|15|1|j|10) and "Moraxella catarrhalis " are the most common. These bacteria often live in the gut and enter the lungs when contents of the gut (such as vomit) are inhaled.The "atypical" bacteria are "Coxiella burnetti ", "Chlamydophila pneumoniae " (ICD10|J|16|0|j|10), "Mycoplasma pneumoniae " (ICD10|J|15|7|j|10), and "Legionella pneumophila ". They are "atypical" because they commonly affect teenagers and young adults, are less severe, and require different antibiotics than typical bacteria such as "Streptococcus pneumoniae".Pathophysiology
Bacteria typically enters the lung with inhalation, though they can reach the lung through the bloodstream if other parts of the body are infected. Often, bacteria live in parts of the
upper respiratory tract and are continually being inhaled into the alveoli. Once inside the alveoli,bacteria travel into the spaces between the cells and also between adjacent alveoli through connecting pores. This invasion triggers theimmune system to respond by sending white blood cells responsible for attacking microorganisms (neutrophil s) to the lungs. The neutrophils engulf and kill the offending organisms but also release cytokines which result in a general activation of the immune system. This results in the fever, chills, and fatigue common in bacterial and fungal pneumonia. The neutrophils, bacteria, and fluid leaked from surrounding blood vessels fill the alveoli and result in impaired oxygen transportation.Bacteria often travel from the lung into the blood stream and can result in serious illness such as
septic shock , in which there is low blood pressure leading to damage in multiple parts of the body including thebrain ,kidney , andheart . They can also travel to the area between the lungs and the chest wall, called thepleural cavity .Treatment
Antibiotic s are the treatment of choice for bacterial pneumonia. The antibiotic choice depends on the nature of the pneumonia, the microorganisms most commonly causing pneumonia in the geographical region, and the immune status and underlying health of the individual. In theUnited Kingdom ,amoxicillin is used as first-line therapy in the vast majority of patients who acquire pneumonia in the community, sometimes with addedclarithromycin . InNorth America , where the "atypical" forms of community-acquired pneumonia are becoming more common,clarithromycin ,azithromycin , orfluoroquinolones as single therapy, have displaced the amoxicillin as first-line therapy. Local patterns of antibiotic-resistance should always be considered when initiating pharmacotherapy. In hospitalized individuals or those with immune deficiencies, local guidelines determine the selection of antibiotics. These antibiotics are typically given through anintravenous line.Treatment of gram-positive organisms
*Streptococcus pneumoniae - amoxicillin (or erythromycin in patients allergic to penicillin); cefuroxime and erythromycin in severe cases.
*Staphylococcus aureus - flucloxacillin (to counteract the organism's β-lactamase)Treatment of gram-negative organisms
*Haemophilus influenzae
*Klebsiella pneumoniae
*Escherichia coli
*Pseudomonas aeruginosa
*Moraxella catarrhalisTreatment of atypical organisms
Most atypical causes of pneumonia require treatment for 14-21 days.
*Chlamydophila pneumoniae - doxycycline
*Chlamydophila psittaci - erythromycin
*Mycoplasma pneumoniae - erythromycin
*Coxiella burnetti - erythromycin
*Legionella pneumophila - erythromycin, withrifampicin sometimes added.People who have difficulty breathing due to pneumonia may require extra
oxygen . An extremely sick individual may requireartificial ventilation and intensive care as life-saving measures while his or her immune system fights off the infectious cause with the help of antibiotics and other drugs. A similar type of infection killedMuppet creatorJim Henson in1990 .
Wikimedia Foundation. 2010.